Opinion: STAT+: A surprising bright spot at the FDA on regulating unproven stem cells
“These successes are surprising, worth discussing, and even celebrating a bit,” STAT Lab Dish columnist Paul Knoepfler writes of the FDA and stem cells.
In June 2025, Robert F. Kennedy Jr. disclosed on a podcast that he had undergone unproven stem cell treatments in the Caribbean to address his throat issue. This revelation raised concerns about the potential for U.S. clinics to sell questionable stem cell therapies without FDA oversight. However, the FDA has demonstrated impressive performance in recent times, particularly on two key fronts concerning the issue of unproven stem cell clinics, despite the prevailing ideologically and politically charged decision-making in medical regulations. This achievement is particularly noteworthy and deserves attention, even celebration.
The United States faces a significant challenge with stem cell clinics and associated entities that peddle a range of unproven and unapproved cellular products. Estimates suggest that there are more than 2,000 such firms operating nationwide. To learn more about this surprising triumph at the FDA, continue reading STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
